C. Fordham von Reyn

Geisel School of Medicine at Dartmouth

Professor of Medicine, Infectious Disease and International Health; Director, DarDar International Programs

C. Fordham von Reyn (“Ford”) MD, DSc (Hon) is Professor of Medicine, Infectious Disease and International Health, and Director, DarDar International Programs at Geisel School of Medicine at Dartmouth. He is a cum laude graduate of Harvard Medical School where he also completed a Fellowship in Infectious Disease. He served with the Centers for Disease Control and subsequently as a founding staff member for the Special Program on AIDS of the World Health Organization. His research has focused on the international epidemiology of mycobacterial infections in HIV and development of an inactivated whole cell TB vaccine. He was PI for the 7-year NIH-sponsored Phase 3 trial of SRL172 which remains the only vaccine shown effective in preventing TB disease. He is currently focused on the development of DAR-901 which represents a scalable manufacturing process for SRL172. A Phase 1 trial of DAR-901 was completed in the US and a Phase 2b trial recently completed in Dar-es-Salaam. He continues his long term Fogarty training grant collaboration with colleagues in Tanzania.

C. Fordham von Reyn

Geisel School of Medicine at Dartmouth

Professor of Medicine, Infectious Disease and International Health; Director, DarDar International Programs

C. Fordham von Reyn (“Ford”) MD, DSc (Hon) is Professor of Medicine, Infectious Disease and International Health, and Director, DarDar International Programs at Geisel School of Medicine at Dartmouth. He is a cum laude graduate of Harvard Medical School where he also completed a Fellowship in Infectious Disease. He served with the Centers for Disease Control and subsequently as a founding staff member for the Special Program on AIDS of the World Health Organization. His research has focused on the international epidemiology of mycobacterial infections in HIV and development of an inactivated whole cell TB vaccine. He was PI for the 7-year NIH-sponsored Phase 3 trial of SRL172 which remains the only vaccine shown effective in preventing TB disease. He is currently focused on the development of DAR-901 which represents a scalable manufacturing process for SRL172. A Phase 1 trial of DAR-901 was completed in the US and a Phase 2b trial recently completed in Dar-es-Salaam. He continues his long term Fogarty training grant collaboration with colleagues in Tanzania.